home / stock / vigl / vigl articles

VIGL Articles, Vigil Neuroscience Inc.

Stock Information
Company Name: Vigil Neuroscience Inc.
Stock Symbol: VIGL
Market: NASDAQ
Website: vigilneuro.com
Menu
VIGL VIGL Quote VIGL Short VIGL News VIGL Articles VIGL Message Board
Get VIGL Alerts

News, Short Squeeze, Breakout and More Instantly...
Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E | Benzinga

Investors often opt for the stock-picking approach that involves stocks with a low price-to-earnings (P/E) ratio. This strategy is based on the not...
Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi | Benzinga

- Sanofi to invest $40 million at an as-converted price of $7.44 per share of common stock- - Sanofi to receive an exclusive right of first negoti...

Vigil Neuroscience to Present in Upcoming June Investor Conferences | Benzinga

WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to h...

Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference | Benzinga

WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to h...
Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer | Benzinga

WATERTOWN, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to...

Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting | Benzinga

WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to...

Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days | Benzinga

WATERTOWN, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to...
Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024 | Benzinga

WATERTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to...

Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024 | Benzinga

Poster highlights clinical overlap of ALSP and multiple sclerosis (MS) and details patients' barriers to genetic testing WATERTOWN, Mass., F...

Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference | Benzinga

WATERTOWN, Mass. , Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to...
Next 10